GlobeNewswire·Apr 27, 2026, 7:30 AM ET

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

MDCX

Medicus Pharma CEO Dr. Raza Bokhari & leadership met with senior U.S. lawmakers on Capitol Hill to advance support for Orphan Drug Designation, Registrational IND approval for SkinJect® in Gorlin Syndrome, & the Rare Disease Pediatric FDA Voucher Program.
Meetings included Chair Brett Guthrie, Member John Joyce, Vice Chair Diana Harshbarger, & Co-Chair Gus Bilirakis from key House Energy & Commerce Committee subcommittees.
Discussions with the Gorlin Syndrome Alliance emphasized the urgent need for non-surgical therapies as patients face lifelong recurrence of basal cell carcinomas & current treatments rely on invasive surgical excision.
SkinJect® is positioned as a localized, repeatable, non-surgical immuno-oncology product aimed at shifting the treatment paradigm for Gorlin Syndrome patients.
Gorlin Syndrome is a rare inherited condition driven by PTCH1 gene mutations causing early & recurrent tumor formation with no current FDA-approved specific therapies.
The Company is advancing regulatory planning to generate decision-grade data for a registrational development pathway in high-burden patient populations.
In August 2025, Medicus signed a non-binding MoU with Helix Nanotechnologies to explore co-developing thermostable infectious disease vaccines combining mRNA technology with the Medicus microneedle platform.
In October 2025, Medicus partnered with the Gorlin Syndrome Alliance to pursue an Expanded Access IND program for compassionate use of SkinJect® in patients with inoperable BCCs.
In December 2025, Medicus signed a non-binding letter of intent with Reliant AI Inc. to develop an AI-driven clinical data analytics platform to support the 2026 Teverelix clinical study.
The company holds a cautionary notice regarding forward-looking statements related to clinical trials, regulatory approvals, & potential collaborations which may not materialize.